22.626 articles found

Method for the Treatment of Neurodegenerative Diseases

PERRIN STEVEN, LINCECUM JOHN MONTEITH, GILL ALAN, VIEIRA FERNANDO.

· 2009-12-04

Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia.

Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S, Hattori N.

Prog Neuropsychopharmacol Biol Psychiatry · 2009-12-03

DOI: 10.1016/j.pnpbp.2009.11.019PMID: 19948198

Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Korkmaz OT, Tunçel N, Tunçel M, Oncü EM, Sahintürk V, Celik M.

J Mol Neurosci · 2009-12-02

DOI: 10.1007/s12031-009-9307-3PMID: 19953344

Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Leehey MA.

J Investig Med · 2009-12-01

DOI: 10.2310/jim.0b013e3181af59c4PMID: 19574929

Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.

Tanaka Y, Kato T, Nishida H, Araki H, Murase M, Nagaki M, Moriwaki H, Inuzuka T.

J Neurol · 2009-12-01

DOI: 10.1007/s00415-009-5220-5PMID: 19575260

Glutamate receptors as therapeutic targets for Parkinson's disease.

Johnson KA, Conn PJ, Niswender CM.

CNS Neurol Disord Drug Targets · 2009-12-01

DOI: 10.2174/187152709789824606PMID: 19702565

PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.

Kumakura Y, Cumming P.

Neuroscientist · 2009-12-01

DOI: 10.1177/1073858409338217PMID: 19793723

Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function.

Alty JE, Clissold BG, McColl CD, Reardon KA, Shiff M, Kempster PA.

Mov Disord · 2009-12-01

DOI: 10.1002/mds.22800PMID: 19890972

Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.

Link S, Paulus W, Bandelow B.

Mov Disord · 2009-12-01

DOI: 10.1002/mds.22846PMID: 19890998

Parkinson's disease and mitochondrial complex I: a perspective on the Ndi1 therapy.

Marella M, Seo BB, Yagi T, Matsuno-Yagi A.

J Bioenerg Biomembr · 2009-12-01

DOI: 10.1007/s10863-009-9249-zPMID: 19904590

Levodopa response in early Parkinson's disease.

Hauser RA, Auinger P, Oakes D, Parkinson Study Group.

Mov Disord · 2009-12-01

DOI: 10.1002/mds.22759PMID: 19908302

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord · 2009-12-01

DOI: 10.1002/mds.22828PMID: 19908310